Abstract 3253
Background
Peptide receptor radionuclide therapy (PRRT) with 177Lutetium (177Lu) -DOTATATE is effective treatment for neuroendocrine tumors (NETs). Dosimetry assessment can be used to maximize the tumour dose, while keeping the dose delivered to critical organs to acceptable levels. The association between tumour absorbed dosimetry (TAD) and progression-free (PFS) and overall survival (OS) is not well understood.
Methods
Single institution retrospective analysis of patients with metastatic NET whom underwent up to 4 cycles of 7.45GBq 177Lu octreotate PRRT. Intra-therapeutic tumour dosimetry was performed with non-gated single photon emission computed tomography (SPECT) to quantify activity at 5 time points after administration of 177 Lu during cycle 1. TAD per injected activity (A0) and estimated total TAD (multiplied by total administered activity of 177Lu) was correlated with OS and PFS using the Kaplan–Meier method and Cox proportional-hazards model.
Results
79 patients were included, primary site: gastroenteric (48%), pancreatic (39%), bronchial (9%), other (4%), ECOG Performance status (PS) 0/1 (94%), Grade: G1 (47%), G2 (42%), G3 (11%), Ki-67≤20% (89%), concurrent chemotherapy use (29%). Mean TAD/A0 was 9(7-11) Gy/GBq. Progressive disease (54%) and death (29%) was seen. Median follow-up of 35 months. Median PFS was 32 [26-38] months. PFS was shorter with increasing ECOG PS (P = 0.02), tumour grade (P < 0.01), Ki-67 (P = 0.01), concurrent chemo-radionuclide therapy (P = 0.02) and reduced TAD (P = 0.036) but not primary site of origin (P = 0.66). A higher TAD led to an improved median PFS in pancreatic (P < 0.01) versus gastroenteric (P = 0.56) NETs. In a multivariate model incorporating ECOG PS, Ki-67 and chemotherapy use, total TAD remained significantly associated with PFS. The mean OS was 40 [36-44] months. OS was shorter with increasing tumour grade (P = 0.05), Ki-67 (P = 0.036) and reduced TAD (P = 0.039).
Conclusions
TAD was independently associated with OS and PFS validating dosimetry assessment in NET patients undergoing PRRT. Prospective refinement of the association on larger, more homogenous cohorts of NET patients is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1049 - The Effect Of Multiple Interventions For Women At Risk For Cervical Cancer On Their Health Responsibility, Beliefs Regarding Cervical Cancer, And Having Screening: A Randomized Controlled Experiment
Presenter: Busra Altinel
Session: Poster Display session 2
Resources:
Abstract
1309 - Quantifying the Effects of the Korean National Cancer Screening Program on Cervical Cancer Mortality
Presenter: Nhung Bui
Session: Poster Display session 2
Resources:
Abstract
1346 - Spread of tumor and adverse events after modified radical hysterectomy for FIGO Stage IB1 cervical cancer patients with tumor diameter preoperatively estimated 2 cm or less: Japan Clinical Oncology Group trial (JCOG1101); exploratory analysis before primary analysis.
Presenter: Takahide Arimoto
Session: Poster Display session 2
Resources:
Abstract
5352 - Impact of Combined Interstitial and Intracavitary Brachytherapy in locally advanced Cervical cancer: A Survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster Display session 2
Resources:
Abstract
2049 - Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer
Presenter: Chel Hun Choi
Session: Poster Display session 2
Resources:
Abstract
1923 - Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)
Presenter: Linda Mileshkin
Session: Poster Display session 2
Resources:
Abstract
3284 - Primary results from CECILIA, a global single-arm phase 2 study evaluating bevacizumab (BEV), carboplatin (C) and paclitaxel (P) for advanced cervical cancer (aCC)
Presenter: Andres Redondo
Session: Poster Display session 2
Resources:
Abstract
843 - Prognostic and clinicopathological significance of PD-L1 in patients with cervical cancer: a meta-analysis
Presenter: Xiaobin Gu
Session: Poster Display session 2
Resources:
Abstract
1020 - Clinical impact of molecular profiling of cervical cancer (CC) patients (pts) in a dedicated Phase I (P1) unit
Presenter: Mariana Scaranti
Session: Poster Display session 2
Resources:
Abstract
872 - Comparative proteomic profiles of cervical cancer and paried paracancerous tissue and the potential effects of DUSP7 over-expression through inhibiting RAS pathway on the biological characteristics of human cervical cancer cell line SIHA
Presenter: Xuan Jiang
Session: Poster Display session 2
Resources:
Abstract